

## Extract Pipeline Report

August 17, 2016 - August 23, 2016

INDICATION	Phase I	Phase II	Phase III	Submitted (NDA / sNDA)	Approved	Cancelled/ Rejected/ Failed/Halted
<b>A</b> Alimentary tract and metabolism						
<b>B</b> Blood and blood forming organs				IndexXa™ (Portola Pharmac.)		
<b>C</b> Cardiovascular system					Upravi® (Actelion Ltd)	
<b>D</b> Dermatologicals						
<b>H</b> Systemic hormonal preparations (excl. sex hormones)						
<b>J</b> General anti-infectives systemic						
<b>K</b> Hospital solutions						
<b>L</b> Antineoplastic and immunomodulating agents		CRLX101 (Cerulean Pharma)		neratinib (Puma Biotech.)		custirsen (OncoGenex)
<b>M</b> Musculo-skeletal system						
<b>N</b> Central nervous system		cannabidiol (Insys Therap.)				
<b>P</b> Parasitology						
<b>R</b> Respiratory system						
<b>S</b> Sensory organs						
<b>T</b> Diagnostic agents						
<b>V</b> Various						

Initiates clinical study in this phase

Has accomplished clinical study in this phase

NDA = New Drug Application

sNDA = Supplementary New Drug Application